---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-090917"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:07:24.734388+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics adopts amended charter and bylaws upon IPO closing

## Summary
- Authorized 200M Class A common and 20M Class B common shares, plus 10M undesignated preferred.
- Classified board with staggered three-year terms; directors removable only for cause with 66 2/3% vote.
- Exclusive forum: Delaware Chancery for derivative/breach claims; federal courts for Securities Act claims.
- Stockholders cannot act by written consent or call special meetings; new procedures for proposals and nominations.

## SEC filing metadata
- accession: 0001193125-24-090917
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000119312524090917/0001193125-24-090917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000119312524090917/d811673d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-090917
- JSON: https://secwatch.observer/filing/0001193125-24-090917.json
- Plain text: https://secwatch.observer/filing/0001193125-24-090917.txt

## Key facts
- Governance Changes
  Contineum Therapeutics, Inc.: Adopted amended and restated bylaws effective upon IPO closing, eliminating stockholder action by written consent and establishing procedures for stockholder proposals and director nominations (effective 2024-04-09).
  - Change: bylaw amendment
  - Effective: 2024-04-09
  source text: Effective as of April 9, 2024 the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000119312524090917/0001193125-24-090917-index.htm
- Governance Changes
  Contineum Therapeutics, Inc.: Amended and restated certificate of incorporation in connection with IPO, including changes to authorized stock, board classification, and exclusive forum provisions (effective 2024-04-09).
  - Change: charter amendment
  - Effective: 2024-04-09
  source text: On April 9, 2024, Contineum Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering (the “IPO”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855175/000119312524090917/0001193125-24-090917-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.